60 Degrees Pharmaceuticals (NASDAQ:SXTP) Receives Neutral Rating from HC Wainwright

HC Wainwright reissued their neutral rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a research note published on Friday,Benzinga reports.

60 Degrees Pharmaceuticals Stock Down 5.6 %

SXTP stock traded down $0.05 during midday trading on Friday, hitting $0.90. 49,447 shares of the company traded hands, compared to its average volume of 246,264. 60 Degrees Pharmaceuticals has a twelve month low of $0.70 and a twelve month high of $18.36. The business has a 50 day simple moving average of $1.09 and a 200-day simple moving average of $0.72. The stock has a market capitalization of $1.67 million, a price-to-earnings ratio of 9.78 and a beta of 4.78.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($4.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.79) by ($1.44). The business had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.11 million. Equities research analysts forecast that 60 Degrees Pharmaceuticals will post -3.17 EPS for the current year.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.